Drugs / Candida antigen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00569231 | Feb 2007 → Jan 2010 | common wart, human papilloma virus infection | University of Arkansas | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04399577 | Jul 2017 → Mar 2019 | common wart | Zagazig University | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT07329907 Comparator | Dec 2023 → Jun 2024 | common wart, human papilloma virus infection | Benha University | Completed | No outcome recorded |
| Phase 2/3 | NCT05254561 Comparator | Nov 2020 → Jun 2021 | — | Zagazig University | Completed | No outcome recorded |
| Phase 3 | NCT03853785 Comparator | Feb 2020 → Feb 2021 | anogenital human papillomavirus infection | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05429151 Comparator | Jun → Nov 2022 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT06749665 Comparator | Dec 2024 → Oct 2025 overdue | common wart | Sohag University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | candida antigen | “Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL.” NCT05429151 ↗ |
| Known as | Candidal antigen | “Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit” NCT03853785 ↗ |
| Modality | Vaccine | “therapeutic vaccination” PMID 26980480 ↗ Mar 2016 |
| Route | Other | “Intralesional injection of 0.3ml candida antigen into largest wart” NCT00569231 ↗ |